| 24.56 -1.66 (-6.33%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 39.58 | 1-year : | 46.23 |
| Resists | First : | 33.88 | Second : | 39.58 |
| Pivot price | 19.51  |
|||
| Supports | First : | 19.73 |
Second : | 10.97 |
| MAs | MA(5) : | 27.92 |
MA(20) : | 17.96 |
| MA(100) : | 9.82 |
MA(250) : | 5.75 |
|
| MACD | MACD : | 4.2 |
Signal : | 3.1 |
| %K %D | K(14,3) : | 67.7 |
D(3) : | 78.4 |
| RSI | RSI(14): 64.7 |
|||
| 52-week | High : | 33.88 | Low : | 1.63 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SMMT ] has closed below upper band by 32.1%. Bollinger Bands are 492% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.73 - 26.89 | 26.89 - 27.01 |
| Low: | 23.61 - 23.8 | 23.8 - 23.95 |
| Close: | 24.3 - 24.59 | 24.59 - 24.81 |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Wed, 18 Sep 2024
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 2.4% - MarketBeat
Wed, 18 Sep 2024
U.S. Markets Declined Wednesday; Summit Therapeutics Posted Biggest Loss - Barron's
Wed, 18 Sep 2024
U.S. Markets Declined Wednesday; Summit Therapeutics Posted Biggest Loss - Barron's
Wed, 18 Sep 2024
Smart Money Is Betting Big In SMMT Options - Benzinga
Mon, 16 Sep 2024
Insider Buying: Summit Therapeutics Co-CEO & Executive Chairman Bought US$75m Of Shares - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 735 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 88.1 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 18,230 (K) |
| Shares Short P.Month | 17,790 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.1 % |
| Return on Equity (ttm) | -102.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -223.28 |
| PEG Ratio | 0 |
| Price to Book value | 90.96 |
| Price to Sales | 0 |
| Price to Cash Flow | -185.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|